La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Alector Croissance future

Future contrôle des critères 2/6

Alector devrait augmenter ses bénéfices et son chiffre d'affaires de 61.1% et de 56.9% par an respectivement. Le BPA devrait croître de de 60.9% par an. Le rendement des capitaux propres devrait être -75.3% dans 3 ans.

Informations clés

61.1%

Taux de croissance des bénéfices

60.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	30.3%
Taux de croissance des recettes	56.9%
Rendement futur des capitaux propres	-75.3%
Couverture par les analystes	Good
Dernière mise à jour	13 Aug 2024

Mises à jour récentes de la croissance future

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

Recent updates

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Jul 11

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

Alector: The GSK Deal Is A Major Value Add

Oct 29

We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate

Sep 27

This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year

Aug 05

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:ALEC - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	142	-193	-227	-142	6
12/31/2025	127	-113	-139	-24	9
12/31/2024	63	-183	-147	-179	10
6/30/2024	55	-161	-218	-217	N/A
3/31/2024	96	-121	-199	-197	N/A
12/31/2023	97	-130	-187	-184	N/A
9/30/2023	96	-141	-190	-187	N/A
6/30/2023	102	-143	-194	-190	N/A
3/31/2023	126	-135	-208	-204	N/A
12/31/2022	134	-133	-24	-20	N/A
9/30/2022	133	-136	-25	-21	N/A
6/30/2022	301	36	471	473	N/A
3/31/2022	227	-29	483	486	N/A
12/31/2021	207	-36	295	299	N/A
9/30/2021	198	-33	297	300	N/A
6/30/2021	21	-212	-189	-186	N/A
3/31/2021	18	-202	-190	-187	N/A
12/31/2020	21	-190	-172	-167	N/A
9/30/2020	22	-169	-154	-148	N/A
6/30/2020	19	-148	-144	-136	N/A
3/31/2020	23	-127	-125	-108	N/A
12/31/2019	21	-105	-115	-99	N/A
9/30/2019	24	-92	-102	-88	N/A
6/30/2019	28	-76	-94	-82	N/A
3/31/2019	28	-62	-84	-81	N/A
12/31/2018	28	-52	126	127	N/A
9/30/2018	22	-45	141	143	N/A
6/30/2018	15	-39	157	159	N/A
3/31/2018	8	-35	N/A	171	N/A
12/31/2017	4	-32	N/A	-18	N/A
12/31/2016	0	-15	N/A	-13	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ALEC devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ALEC devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ALEC devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ALEC ( 56.9% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ALEC ( 56.9% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: ALEC devrait être non rentable dans 3 ans.

Alector Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

Consensus revenue estimates decrease by 37%, EPS upgraded

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Recent updates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded

Co-Founder notifies of intention to sell stock

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Alector: Good Data, Huge Cash, No Near Term Catalyst

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold US$133k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Price target decreased by 12% to US$15.40

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Consensus revenue estimates increase by 244%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Price target decreased by 13% to US$14.33

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold US$94k worth of stock

Consensus revenue estimates decrease by 24%

Consensus revenue estimates fall by 79%

Key Executive recently sold US$84k worth of stock

Price target decreased by 20% to US$16.94

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$21.44

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Consensus revenue estimates increase by 13%

Price target decreased to US$24.96

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two Programs Pursuant to the Co-Development and Option Agreement

AbbVie ends partnership with Alector for Alzheimer’s candidate

Alector: Potential In Neurology And Cancer Treatments

Price target decreased to US$28.59

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

Consensus revenue estimates fall by 26%

Price target decreased to US$31.26

First quarter 2022 earnings: EPS and revenues miss analyst expectations